A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 diabetes, providing ...

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable ...

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...

The use of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity is associated with an ...

In a recent study published in Nature, researchers developed the MK-801 bimodal drug that successfully cures obesity, hyperglycemia, and dyslipidemia in mouse models of metabolic illness by combining ...

Xeris Pharmaceuticals has taken a big step toward receiving approval for its ready-to-use formulation of glucagon in the EU. The injectable formulation, branded Ogluo, received a positive opinion from ...

Please provide your email address to receive an email when new articles are posted on . Fewer people with diabetes filled glucagon prescriptions in 2021 compared with 2011, though increases were seen ...

Indianapolis-based pharma giant Eli Lilly has announced the company now offers an Android version of its app, called Glucagon, which is designed to help caregivers and providers treat people with ...

An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - a type of ...

INDIANAPOLIS, Sept. 24, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is voluntarily recalling lot D239382D, Expiration April 2022, of Glucagon Emergency Kit for Low Blood Sugar (Glucagon for ...